$1.39
0.71% yesterday
Nasdaq, Dec 08, 10:00 pm CET
ISIN
US5288723027
Symbol
LXRX

Lexicon Pharmaceuticals, Inc. Stock price

$1.39
-0.03 2.11% 1M
+0.64 86.55% 6M
+0.65 88.22% YTD
+0.65 88.83% 1Y
-0.78 35.94% 3Y
-1.69 54.87% 5Y
-11.58 89.28% 10Y
-28.57 95.36% 20Y
Nasdaq, Closing price Mon, Dec 08 2025
-0.01 0.71%
ISIN
US5288723027
Symbol
LXRX
Industry

Key metrics

Basic
Market capitalization
$505.1m
Enterprise Value
$445.7m
Net debt
positive
Cash
$116.0m
Shares outstanding
363.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.1 | 9.8
EV/Sales
6.3 | 8.6
EV/FCF
negative
P/B
4.2
Financial Health
Equity Ratio
48.9%
Return on Equity
-137.3%
ROCE
-36.3%
ROIC
-
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$70.9m | $51.8m
EBITDA
$-66.2m | $-79.7m
EBIT
$-66.9m | $-79.5m
Net Income
$-68.6m | $-62.6m
Free Cash Flow
$-72.6m
Growth (TTM | estimate)
Revenue
1,254.9% | 66.6%
EBITDA
68.5% | 59.5%
EBIT
68.3% | 59.7%
Net Income
68.3% | 68.8%
Free Cash Flow
65.2%
Margin (TTM | estimate)
Gross
99.4%
EBITDA
-93.5% | -154.0%
EBIT
-94.4%
Net
-96.8% | -120.8%
Free Cash Flow
-102.4%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
18.9%
Employees
103
Rev per Employee
$300.0k
Show more

Is Lexicon Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Lexicon Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

Buy
73%
Hold
27%

Financial data from Lexicon Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
71 71
1,255% 1,255%
100%
- Direct Costs 0.42 0.42
24% 24%
1%
70 70
1,340% 1,340%
99%
- Selling and Administrative Expenses 61 61
58% 58%
86%
- Research and Development Expense 76 76
5% 5%
108%
-66 -66
69% 69%
-93%
- Depreciation and Amortization 0.63 0.63
13% 13%
1%
EBIT (Operating Income) EBIT -67 -67
68% 68%
-94%
Net Profit -69 -69
68% 68%
-97%

In millions USD.

Don't miss a Thing! We will send you all news about Lexicon Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexicon Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025, at the Mayflower Hotel in Washington, D.C.
Positive
Seeking Alpha
6 days ago
Lexicon Pharmaceuticals currently offers three late-stage assets - Zynquista, Inpefa, and pilavapadin - each with high-reward potential but significant regulatory and commercial risks. Zynquista's renewed FDA engagement for Type 1 diabetes could enable resubmission in early 2026, but commercial execution and reimbursement remain key hurdles. Inpefa's HCM Phase III readout is expected in Q1'27, ...
Neutral
GlobeNewsWire
14 days ago
THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET and at the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET.
More Lexicon Pharmaceuticals, Inc. News

Company Profile

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Head office United States
CEO Michael Exton
Employees 103
Founded 1995
Website www.lexpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today